Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Eli Lilly (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will join a fireside chat at 3:20 p.m. Eastern time.
A live audio webcast and a 90-day replay will be available on Lilly's investor website in the Webcasts & Presentations section.
Positive
- None.
Negative
- None.
News Market Reaction – LLY
In the May 27 session, LLY gained 1.71%, reflecting a mild positive market reaction. Our momentum scanner triggered 56 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Portfolio acquisitions | Positive | -0.0% | Announced three vaccine-focused acquisitions to expand infectious disease portfolio. |
| May 25 | Clinical data update | Positive | -0.0% | Interim Phase 1b data for VERVE-102 showed strong LDL-C and PCSK9 reductions. |
| May 21 | Oncology conference plans | Positive | +2.2% | Detailed ASCO plans highlighting Phase 3 data and multiple oncology programs. |
| May 21 | Obesity Phase 3 data | Positive | +2.2% | Topline Phase 3 TRIUMPH-1 results showed large weight loss with retatrutide. |
| May 18 | Investor conference | Neutral | -1.7% | Announcement of a Bernstein fireside chat and webcast availability for investors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent major clinical and obesity data (e.g., retatrutide, VERVE-102) coincided with positive or stable moves, while acquisitions and conference appearances have shown more muted or mixed price reactions.
Over the last few weeks, LLY reported several catalysts: sizeable infectious disease acquisitions on May 26, strong Phase 1b data for VERVE-102 on May 25, and pivotal Phase 3 obesity results for retatrutide on May 21, alongside an extensive ASCO oncology presence. It also announced participation in Bernstein’s conference on May 18. Today’s Goldman Sachs conference participation mirrors that pattern of frequent investor and scientific visibility rather than a new fundamental inflection.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to: | Megan MacCauley; maccauley_megan@lilly.com; 463-202-1516 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-302783288.html
SOURCE Eli Lilly and Company